BioRestorative Therapies Inc. (NV) (BRTX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, BioRestorative Therapies Inc. (NV) (NASDAQ: BRTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.40 (-11.37% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BRTX ranks #448 in composite RQD confidence.
Within the Health Care sector (Managed Health Care), BRTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 93.4%, and ROIC of -35.0%. By comparison, PPCB (Propanc Biopharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M) and ELAB (PMGC Holdings Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M). Among the 5-stock peer group, BRTX leads on earnings multiple (N/A) while BRTX leads on capital efficiency (-35.0% ROIC).
Per BRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001505497), BioRestorative Therapies Inc. (NV) generated $359.7K in revenue (-10.3% YoY), -$14.2M in net income, and -$10.9M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.9 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BRTX currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.51) and Max Pain ($1.47) forces dealer call-delta covering toward $32.55.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BioRestorative Therapies Inc. (NV) (BRTX) dropped -11.37% to $1.40, trading at 2% of its 52-week range ($1.28 – $31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Com
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILL
Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. (
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety s
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Stre
Yahoo Finance coverage on BRTX stock catalysts, institutional flow, and earnings outlook.
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- BioRest
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -10.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BRTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BRTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BioRestorative Therapies Inc. (NV) (BRTX) ranks #448 by composite RQD confidence (44/100, grade D) and #993 by equity capitalization ($2.2M). Within this direct 5-issuer industry benchmark cohort, BRTX leads on earnings valuation at N/A trailing P/E, while BRTX leads on capital efficiency and profitability with -35.0% ROIC and 93.4% gross margin. BDRX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with BRTX at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BRTX
ACTIVE
BioRestorative Therapies Inc. (NV) | D | 44/100 | — | 93.4% | -35.0% | -11.37% | $2.2M | Benchmark Subject |
| PPCB Propanc Biopharma Inc. | E | 32/100 | — | — | -35.0% | -12.80% | $2.2M | /ppcb-vs-brtx → |
| ELAB PMGC Holdings Inc. | E | 27/100 | — | 31.4% | -35.0% | -1.51% | $2.1M | /elab-vs-brtx → |
| REVB Revelation Biosciences Inc. | D- | 36/100 | — | — | -35.0% | +7.47% | $2.1M | /revb-vs-brtx → |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | D | 49/100 | — | — | — | -12.05% | $2.0M | /bdrx-vs-brtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioRestorative Therapies Inc. (NV) (BRTX) reported GAAP revenue of $359.7K (-10.3% vs. FY2024 revenue of $401.0K , and +146.7% cumulative change since FY2023) , GAAP net income of -$14.2M, operating cash flow of -$10.8M, and free cash flow of -$10.9M (-30.8% YoY). On the balance sheet, BRTX closed FY2025 with $4.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $359.7K | -$14.2M | -$10.8M | -$10.9M | $4.1M | — |
| FY2024 (FY) | 2024-12-31 | $401.0K | -$9.0M | -$8.2M | -$8.3M | $12.3M | — |
| FY2023 (FY) | 2023-12-31 | $145.8K | -$10.4M | -$6.4M | -$6.4M | — | — |
As of 2026-11-02, BioRestorative Therapies Inc. (NV) (NASDAQ: BRTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.40 (-11.37% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BRTX ranks #448 in composite RQD confidence.
Within the Health Care sector (Managed Health Care), BRTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 93.4%, and ROIC of -35.0%. By comparison, PPCB (Propanc Biopharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M) and ELAB (PMGC Holdings Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M). Among the 5-stock peer group, BRTX leads on earnings multiple (N/A) while BRTX leads on capital efficiency (-35.0% ROIC).
Per BRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001505497), BioRestorative Therapies Inc. (NV) generated $359.7K in revenue (-10.3% YoY), -$14.2M in net income, and -$10.9M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BRTX last traded at $1.40 (-11.37% on volume of 28,799 shares), positioning the stock -44.22% below its 50-day simple moving average ($2.51) and -77.74% below its 200-day simple moving average ($6.29). Across its 52-week range of $1.28 to $31.00, BRTX sits at the 0.4% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.23 to $1.57).
Why BRTX Stock dropped -11.37% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, BRTX scores 44 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 14/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Taken together, the weakest pillars are the cash engine and insider conviction, which are the two areas that most directly reflect whether the business generates value and whether those closest to it are committing capital. For a prospective investor evaluating the stock today, the rating signals that the fundamental cash profile and insider behavior do not currently support the thesis, and that the institutional flow pillar, while the strongest, does not offset the deficits. Upside drivers would need to come from a turnaround in cash generation, which the source data does not evidence. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. The rating itself is an analytical output and is not personalized financial advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.4M | $-15.6M | $-14.2M | N/A | $-10.9M | $1.5M | N/A |
| FY 2024 | $0.4M | $-11.6M | $-9.0M | N/A | $-8.3M | $0.5M | N/A |
| FY 2023 | $0.1M | $-15.2M | $-10.4M | N/A | $-6.4M | N/A | N/A |
Per the SEC financials, operating and net losses appear in every reported period, and the gross margin is listed at 93.4%, while operating and net margins are each -60%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5 with a Piotroski F-Score of 2/9. Debt-to-equity is 0.5 per the forensic pillar, though the debt line in the SEC financials is N/A for all periods, so the composition of that ratio is not available in source data. Cash is reported at $1.5M for FY 2025 versus $0.5M for FY 2024.
Per the Butterfly Supply-Chain Graph, no supply chain is mapped (supply_chain: NONE), no butterfly links are recorded, and no proprietary signals are present. Sector context is limited to Health Care and Managed Health Care. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. Beta of 1.0 per the market data indicates market-level sensitivity, but sector correlation coefficients are not available in source data.
Real-time company headlines, analyst actions, and sector developments for BioRestorative Therapies Inc. (NV) (BRTX) • Click "Debate This Headline" to argue it in the Roar Pit below
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Com
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILL
Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. (
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety s
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Stre
Yahoo Finance coverage on BRTX stock catalysts, institutional flow, and earnings outlook.
Welcome to the BRTX (BioRestorative Therapies Inc. (NV)) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Managed Health Care. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BRTX, but look at what you are paying: current EV/EBITDA multiples with 93.4% gross margins. Unless BioRestorative Therapies Inc. (NV) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BRTX, the market is fixating on short-term headline noise in Managed Health Care and ignoring the balance sheet and cash flow trajectory. At $1.40 (52-wk range $1.28 - $31.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).